AUG 07, 2018 10:00 PM PDT

Renal Cell Carcinoma and Myelodysplastic Syndrome Show Epigenetic Association

WRITTEN BY: Mauri Brueggeman
1 1 54

Hypermethylation has been documented in some myeloid disorders including myelodysplastic syndrome (MDS) and in renal cell carcinoma (RCC).  A group at the Mayo Clinic noticed the epigenetic marking patterns between these vastly different conditions and wondered if there was a connection.  The group found that there was a strong association.

Epigenetics, as a field, is being embraced and has been studied for numerous years.  The term “epigenetics” has been around for nearly three quarters of a century, being coined in 1942 by a British developmental biologist named C.H. Waddington.  Some of the genetic underpinnings of heritable changes in gene expression are known but much, as of yet, is less well understood.  Studies have shown that the modification of gene expression results in a variety of conditions that can be congenital or acquired.  The most studied epigenetic change is DNA methylation whereby a methyl group is covalently transferred to the C-5 position of the cytosine ring within a strand of DNA.  DNA methylation can occur within any area of the genome on any given cytosine in mammals; however, most of the methylation takes place in CpG dinucleotide regions which are sequences of DNA with a cytosine (C) nucleotide followed by guanine (G) molecule connected by a phosphodiester bond (“p”).  

In RCC and some myeloid cancers, there is atypical DNA hypermethylation in those CpG regions within tumor suppressor gene promotor regions which inactivate many cellular pathways which lead to cancer.  The researchers at the Mayo Clinic used an explorer database and the Dusseldorf MDS registry to identify patients with a history of both RCC and hematologic malignancies including MDS.  They analyzed clinical features and long-term outcomes; 59 patients were identified as having both RCC and a myeloid malignancy history.  Out of the total, 38 of 59 patients had MDS diagnoses; there was a predominant male to female ratio with a nearly 4.5 times likelihood of a male versus female developing a myeloid malignancy after RCC.  The researchers documented a strong association between RCC and MDS with RCC being the initial diagnosis at a median age of 64 with further development of a MDS in their mid-seventies.  The group concluded that patients with a history of RCC appear to have a significant risk of a MDS emerging later in life compared to the overall population.

Sources: Clinical Genitourinary Cancer,  Cold Spring Harbor Perspectives, Environmental Health Perspectives, Genes and Cancer, Oncogene,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
MAY 01, 2018
Cancer
MAY 01, 2018
CNS Tumor Cells Destroyed by Zika Virus
CNS tumor classification changed in 2016 to incorporate tumor molecular markers. Researchers look at CNS tumor cells and destroy them with Zika virus infection
MAY 21, 2018
Cancer
MAY 21, 2018
Epigenetics & Cancer: DNA Modification Impacts
Epigenetics is defined and outlined as important in gene expression and a possible cause for cancer development & as a target for cancer detection. Researchers are looking at new approaches.
JUN 05, 2018
Cancer
JUN 05, 2018
Early Breast Cancer Patients Do Not Gain Response Advantage with Chemotherapy
Phase III clinical trial research shows evidence that early breast cancer patients with common breast cancer type do not need chemotherapy & hormone therapy combo; hormone therapy is enough
JUN 16, 2018
Cancer
JUN 16, 2018
Lung Cancer Rates Increasing in White and Hispanic Young Women
Lung cancer has long been tied to smoking and had a higher incidence in men than women. A new study shows rates of lung cancer are increasing in some groups of young women.
JUN 25, 2018
Cancer
JUN 25, 2018
B-cell Lymphoma Develops After MPN JAK1/2 Therapy
Patients with myeloproliferative neoplasms treated with JAK1/2 inhibitor therapy are at increased risk of developing aggressive B-cell lymphoma due to pre-existing B-cell clone specifically a
JUL 31, 2018
Cancer
JUL 31, 2018
Can Medicine Prevent Cisplatin-associated Hearing Loss for Pediatric Cancer Patients?
Researchers have determined that sodium thiosulfate's antioxidant properties can prevent hearing loss in pediatric cancer patients being treated with Cisplatin.
Loading Comments...